XNAS
PHVS
Market cap972mUSD
May 01, Last price
17.85USD
1D
-3.41%
1Q
1.42%
IPO
-37.80%
Name
Pharvaris NV
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
3.81%
Rev. gr., 5y
%
Revenues
0k
Net income
-101m
L+32.15%
CFO
-120m
L+29.10%
Profile
Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist that is in Phase II clinical trial for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks and is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients and is under Phase 1 clinical trial. It operates in the Netherlands, Switzerland, and the United States. The company was incorporated in 2015 and is based in Leiden, the Netherlands.
Valuation
Title EUR in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | |
| Income | ||||||||
Revenues | ||||||||
Cost of revenue | 97,166 | 86,865 | ||||||
Unusual Expense (Income) | ||||||||
NOPBT | (97,166) | (86,865) | ||||||
NOPBT Margin | ||||||||
Operating Taxes | 1,049 | 679 | ||||||
Tax Rate | ||||||||
NOPAT | (98,215) | (87,544) | ||||||
Net income | (100,875) 32.15% | (76,333) 78.64% | ||||||
Dividends | ||||||||
Dividend yield | ||||||||
Proceeds from repurchase of equity | 2,244 | 342,911 | 9,610 | |||||
BB yield | -31.84% | -2.54% | ||||||
| Debt | ||||||||
Debt current | 222 | 195 | 187 | |||||
Long-term debt | 1,501 | 282 | 686 | |||||
Deferred revenue | ||||||||
Other long-term liabilities | ||||||||
Net debt | (279,005) | (390,754) | (160,964) | |||||
| Cash flow | ||||||||
Cash from operating activities | (120,130) | (93,049) | (67,163) | |||||
CAPEX | (538) | (88) | (124) | |||||
Cash from investing activities | (538) | (90) | (124) | |||||
Cash from financing activities | 2,677 | 325,393 | 8,650 | |||||
FCF | (1,025) | (98,044) | (87,819) | |||||
| Balance | ||||||||
Cash | 280,728 | 391,232 | 161,837 | |||||
Long term investments | ||||||||
Excess cash | 280,728 | 391,232 | 161,837 | |||||
Stockholders' equity | (355,881) | (231,764) | (139,918) | |||||
Invested Capital | 624,503 | 616,051 | 288,447 | |||||
ROIC | ||||||||
ROCE | ||||||||
| EV | ||||||||
Common stock shares outstanding | 38,392 | 33,586 | ||||||
Price | 19.17 -31.66% | 28.05 149.33% | 11.25 -21.82% | |||||
Market cap | 1,076,886 185.01% | 377,842 -13.66% | ||||||
EV | 686,132 | 216,878 | ||||||
EBITDA | 270 | (96,908) | (86,712) | |||||
EV/EBITDA | ||||||||
Interest | 20 | 16 | ||||||
Interest/NOPBT | ||||||||